1867957
Last Update Posted: 2013-06-05
Recruiting has ended
Males accepted | 18 Years-45 Years |
20 Estimated Participants | No Expanded Access |
Interventional Study | Accepts healthy volunteers |
Efficacy and Safety of Anthrax Vaccine, GC1109
BACKGROUND The newly developed anthrax vaccine GC1109 has been proven safe and effective in preclinical studies.
OBJECTIVE
- To evaluate the immunogenicity and safety of the anthrax vaccine GC1109 in healthy male volunteers.
STUDY DESIGN
- single-blinded
- randomized
- placebo controlled
- phase 1 study
Eligibility
Relevant conditions:
Anthrax
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov